The JAK/STAT signaling pathway contributes to the immune response which causes GvHD1
GvHD is the primary immunological complication to allogeneic HSCT , it is the second leading cause of death in patients undergoing allogeneic HSCT, behind only mortality from primary disease2.
There are two types of GvHD: acute and chronic. Acute GvHD manifests within 100 days of HSCT. Chronic GvHD has a delayed onset beyond 100 days Although features of aGVHD and cGVHD may coexist3.
In GvHD, donor derived immune cells view the recipient’s body as foreign and attack normal cells4.
JAK-STAT Signaling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for GvHD pathogenesis1.
GvHD, graft-versus-host disease ; HSCT , hematopoietic stem cell transplantation
References
Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, The Journal of the American Society of Hematology. 2013 Aug 15;122(7):1192-202.
McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Science translational medicine. 2015 Mar 25;7(280):280rv2-.
Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Therapeutic advances in hematology. 2013 Dec;4(6):366-78.
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. The Lancet. 2009 May 2;373(9674):1550-61.
Approved by Egyptian Drug Authority: HF0424OA5945/052026 Invalidation date: 23/02/2028 Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
HF0424OA5945/052026 |